Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial

pharmaceutical-technologyJune 25, 2021

Tag: Tiziana , FHI , COVID-19 , foralumab

PharmaSources Customer Service